Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Wino115on Nov 10, 2021 7:51pm
142 Views
Post# 34112829

RE:RE:RE:RE:RE:RE:RE:What is it?

RE:RE:RE:RE:RE:RE:RE:What is it?Paul -- if you're reading this in preparation for tomorrow, please, please, please smile at the appropriate times, say how long the trials been running, how many patients dosed, the current dosage level and that, if it is factual, from what you see everything "looks consistent with the preclinical work and conclusions"!   Condition it how ever you want, but don't ignore your shareholders.  Even just say everythings still safe and you're pumping the hell out the patients with your PDC!  It's high time you start prepping the market before the market ignores more good news!

archeo753 wrote: With all of the hiring that Paul has done in the last year it feels like he is building the company for sustainability and growth, over the long haul, not setting it up for a quick sale.   Just my opinion for whatever that's worth. 


realitycheck4u wrote: I would suggest to you that I have been the most critical over the years. Yet I am with you all now being the most hopeful, and likely also one of the biggest supporters of PL. I think he is our man, and I think he is shaking the trees as much as possible at the company. He maybe should have cut Leah lose a while back and we have dead wood on the BOD, but I think he knows this. He just cannot deal with the drama right now.  Give Paul Tim.  

If this trial goes well, I think he could potentially also be the person to not sell the company, and pull off a Qualcomm.  Just license it out, sit back, and make a fortune. I would like that approach.

CreatingApe wrote:
why are you always trying to get Rusty and thera in trouble? One, hes probably our best resource here. Two, thera seems about as tight lipped as any company in the world. Three, why TF would you try to get a company you are invested in into trouble? I've seen you make several accusations over the years you should probably quit it. Lest we loose the valuable information Rusty shares with us. It's really baffling behavior.

 




<< Previous
Bullboard Posts
Next >>